GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Invokamet

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Invokamet - product and source limitations

These rules apply to a metformin-containing combination. Confirm the immediate-release formulation, interactions and contrast instructions.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Invokamet - product and source limitations

Official source

Invokamet - labeled renal guidance

Renal action and limits

Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets
Indexed GFR/eGFR, mL/min/1.73 m2

Action or finding
Below eGFR 45, initiation is not recommended. At 45 to <60, the renal table caps canagliflozin at 100 mg/day. At 30 to <45, reassess continuation and use the same cap. Below 30, discontinue; use is contraindicated.
Limits and monitoring
These rules apply to a metformin-containing combination. Confirm the immediate-release formulation, interactions and contrast instructions.
Before use
Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 32, effective 2026-08-24; posted Aug 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage All evidence
Product / population
Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets
Renal measure
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 32, effective 2026-08-24; posted Aug 25, 2026
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Renal guidance: 2.3, Table 2

Below eGFR 45, initiation is not recommended. At 45 to <60, the renal table caps canagliflozin at 100 mg/day. At 30 to <45, reassess continuation and use the same cap. Below 30, discontinue; use is contraindicated. These rules apply to a metformin-containing combination. Confirm the immediate-release formulation, interactions and contrast instructions.

Source revision: DailyMed SPL version 32, effective 2026-08-24; posted Aug 25, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Invokamet - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Invokamet - selected RX renal passage

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Invokamet - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Invokamet - product and source limitations

These rules apply to a metformin-containing combination. Confirm the immediate-release formulation, interactions and contrast instructions.

How to use this: Apply only to the stated formulation, indication and renal population.

Invokamet - labeled renal guidanceInvokamet - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeInvokamet - labeled renal guidanceInvokamet - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1

Product identity and scope

Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

RDM73-invokamet-identity-1 · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Invokamet - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 32, effective 2026-08-24; posted Aug 25, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2.3, Table 2

Below eGFR 45, initiation is not recommended. At 45 to <60, the renal table caps canagliflozin at 100 mg/day. At 30 to <45, reassess continuation and use the same cap. Below 30, discontinue; use is contraindicated. These rules apply to a metformin-containing combination. Confirm the immediate-release formulation, interactions and contrast instructions.

RDM73-invokamet-official-1 · Source locator: Renal guidance: 2.3, Table 2

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 32, effective 2026-08-24; posted Aug 25, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
c408f7920333b3824cb4efdf09f339f1eba1ca4680862d08afb81977ec1dcdb7
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Invokamet - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Canagliflozin/metformin (Invokamet), adult immediate-release oral tablets

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror describes an expected early creatinine increase and recommends evaluation for AKI if the pattern is atypical.

RDM73-invokamet-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/invokamet-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
2e7d88737393af9f21e2366a4352b7eb726a4dc321d7ad867e1b160ea9b3911d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6868666b-c25e-40d1-9d1f-306bbe9390c1
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
cf1e146b512a47d350a7cd1904f9f2517f5672b4eb4f3dbeee52da594207f152
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top